Top

Welcome to Molecular Templates

Engineered Toxin Body Technology

The Engineered Toxin Bodies (ETBs) platform represent a new class of targeted biologic therapies with unique biological properties.

  • Forced Internalization
  • Novel Mechanism of action
  • De-immunized Toxin Scaffold
  • Payload Delivery

Read More

MT-3724

MT-3724 is Molecular Templates’ lead drug candidate. MT-3724 is currently in Phase 1 clinical trials at the Memorial Sloan-Kettering Cancer Center, the MD Anderson Cancer Center, the Lineberger Comprehensive Cancer Center at the University of North Carolina, and the University of Arizona.

Read More

Pipeline

Product Candidate
  • MT-3724
  • MT-4019
  • MT-2289
  • MT-5050
  • MT-6868
Target
  • CD20
  • CD38
  • HER2
  • PD-L1
  • CD45

Read More

Immuno-Oncology

ETBs self-route to the cytosol where they can intersect with the cell’s antigen presentation pathway. Molecular Templates is exploting the localization of ETBs to the cytosol to create a novel immuno-oncology approach we call Antigen Seeding Technology (AST).

  • Antigen Seeding Technology (AST)
  • Recruiting a high avidity native response to the Tumor

Read More

ENGINEERED TOXIN BODIES

Antibody-like target specificity

Destroy tumor cells via novel mechanism of action

Toxin scaffold derived from Shiga-Like Toxin A-Subunit (SLT-A)

De-immunized to prevent adaptive and innate immune recognition

Capable of inducing their own internalization

Able to deliver payloads to intracellular compartments

RECENT NEWS